<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">30695970</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>05</Month>
        <Day>22</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>05</Month>
        <Day>22</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1087-2108</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>24</Volume>
            <Issue>11</Issue>
            <PubDate>
              <Year>2018</Year>
              <Month>Nov</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Dermatology online journal</Title>
          <ISOAbbreviation>Dermatol Online J</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Morgellons disease: insights into treatment.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">13030/qt38x1k82r</ELocationID>
        <Abstract>
          <AbstractText>Morgellons disease is a disfiguring and distressing condition. Patients commonly present with multiple, non-healing, cutaneous wounds. Patients report protruding fibers or other objects as the source and often provide samples to the clinician. Originally the etiology of this condition was broad and debated ranging from infectious to psychiatric. This article reviews current treatments and details our approach to treatment, aiming to aid clinicians with useful pharmacotherapy and adherence techniques when treating patients with Morgellons disease. Although current opinions have consolidated to the psychiatric spectrum, Morgellons treatment remains difficult and unstandardized with most evidence from retrospective reviews and a handful of case reports. Having considerable overlap with delusions of parasitosis, treatments have consisted of various antipsychotics and antibacterial wound care. Many antipsychotics have been selected owing to additional antipruritic or analgesic benefits. Generally, low-doses are used to minimize the risk of side effects. Risperidone or trifluoperazine can provide relief to patients especially when paired with adjuvant therapies, strong doctor-patient relationships, and a multidisciplinary approach.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Aung-Din</LastName>
            <ForeName>David</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sahni</LastName>
            <ForeName>Dev R</ForeName>
            <Initials>DR</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jorizzo</LastName>
            <ForeName>Joseph L</ForeName>
            <Initials>JL</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Feldman</LastName>
            <ForeName>Steven R</ForeName>
            <Initials>SR</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Research, Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, North Carolina Department of Pathology, Wake Forest School of Medicine, Winston-Salem, North Carolina Department of Social Sciences &amp; Health Policy, Wake Forest School of Medicine, Winston-Salem, North Carolina. sfeldman@wakehealth.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>11</Month>
          <Day>15</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Dermatol Online J</MedlineTA>
        <NlmUniqueID>9610776</NlmUniqueID>
        <ISSNLinking>1087-2108</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>214IZI85K3</RegistryNumber>
          <NameOfSubstance UI="D014268">Trifluoperazine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>L6UH7ZF8HC</RegistryNumber>
          <NameOfSubstance UI="D018967">Risperidone</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055118" MajorTopicYN="Y">Medication Adherence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055535" MajorTopicYN="N">Morgellons Disease</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010817" MajorTopicYN="Y">Physician-Patient Relations</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014268" MajorTopicYN="N">Trifluoperazine</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014946" MajorTopicYN="N">Wound Infection</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>12</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2018</Year>
          <Month>12</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>1</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>1</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>5</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">30695970</ArticleId>
        <ArticleId IdType="pii">13030/qt38x1k82r</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
